{
    "Rank": 568,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01729676",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "000059"
                },
                "Organization": {
                    "OrgFullName": "Ferring Pharmaceuticals",
                    "OrgClass": "INDUSTRY"
                },
                "BriefTitle": "Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation",
                "OfficialTitle": "Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation: FACT STUDY",
                "Acronym": "FACT"
            },
            "StatusModule": {
                "StatusVerifiedDate": "July 2014",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "May 2013"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "May 2014",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "May 2014",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "October 23, 2012",
                "StudyFirstSubmitQCDate": "November 14, 2012",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "November 20, 2012",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "July 16, 2014",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "July 17, 2014",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Ferring Pharmaceuticals",
                    "LeadSponsorClass": "INDUSTRY"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region. The main objective is to describe the distribution of prostate cancer stages when first line hormonal therapy is introduced (overall and by region)."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Prostate Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Cohort"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Prospective"
                        ]
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "315",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Group A",
                            "ArmGroupDescription": "Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Degarelix or GnRH agonist"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Degarelix or GnRH agonist",
                            "InterventionDescription": "Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Group A"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Estimated percentage of different prostate cancer stages (overall and by region)",
                            "PrimaryOutcomeDescription": "The stages of prostate cancer are classified as locally advanced, metastatic and biological recurrence.",
                            "PrimaryOutcomeTimeFrame": "During a single consultation when first-line prostate cancer hormone therapy is started"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "The characteristics of the patients with prostate cancer by region",
                            "SecondaryOutcomeDescription": "Characteristics are described by demography, tumour characteristics, Gleason score, D'Amico score, prostate specific antigen (PSA), Testosterone and treatment history",
                            "SecondaryOutcomeTimeFrame": "During a single consultation when first-line prostate cancer hormone therapy is started"
                        },
                        {
                            "SecondaryOutcomeMeasure": "The influence of regional factors on staging of prostate cancer",
                            "SecondaryOutcomeDescription": "The regional influence will be demonstrated by modelling the probability of a patient being at one of the cancer stages (locally advanced cancer, metastatic cancer, biological recurrence).",
                            "SecondaryOutcomeTimeFrame": "During a single consultation when first-line prostate cancer hormone therapy is started"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nPatients with histologically demonstrated prostatic adenocarcinoma.\nPatients never previously treated with hormonal therapy for prostate cancer.\nPatients eligible for hormonal therapy after initial consultation (alone or in combination with curative treatment).\nPatients agreeing to the collection of personal health data for the purposes of the study.\nPatients with locally advanced or metastatic prostatic cancer tumours or a biological recurrence after curative treatment.\n\nExclusion Criteria:\n\nPatients participating in a clinical study involving prostate cancer at the time of inclusion in the investigation.\nPatients having received or currently receiving hormonal treatment for prostate cancer (surgical castration or other hormonal manipulation, including GnRH receptor antagonists, antiandrogens, oestrogens, 5 alpha reductase inhibitors).",
                "HealthyVolunteers": "No",
                "Gender": "Male",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Men never previously treated with hormononal therapy for prostate cancer",
                "SamplingMethod": "Non-Probability Sample"
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Clinical Development Support",
                            "OverallOfficialAffiliation": "Ferring Pharmaceuticals",
                            "OverallOfficialRole": "Study Director"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "H\u00f4pital Robert Boulin",
                            "LocationCity": "Libourne",
                            "LocationCountry": "France"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000011471",
                            "ConditionMeshTerm": "Prostatic Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000005834",
                            "ConditionAncestorTerm": "Genital Neoplasms, Male"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005832",
                            "ConditionAncestorTerm": "Genital Diseases, Male"
                        },
                        {
                            "ConditionAncestorId": "D000091662",
                            "ConditionAncestorTerm": "Genital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000011469",
                            "ConditionAncestorTerm": "Prostatic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000052801",
                            "ConditionAncestorTerm": "Male Urogenital Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M14025",
                            "ConditionBrowseLeafName": "Prostatic Neoplasms",
                            "ConditionBrowseLeafAsFound": "Prostate Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M8636",
                            "ConditionBrowseLeafName": "Genital Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2877",
                            "ConditionBrowseLeafName": "Genital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8634",
                            "ConditionBrowseLeafName": "Genital Diseases, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14023",
                            "ConditionBrowseLeafName": "Prostatic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26785",
                            "ConditionBrowseLeafName": "Male Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M9479",
                            "InterventionBrowseLeafName": "Hormones",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}